{"id":46120,"date":"2022-07-13T14:01:51","date_gmt":"2022-07-13T12:01:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/"},"modified":"2022-07-13T14:01:51","modified_gmt":"2022-07-13T12:01:51","slug":"renovorx-launches-the-renovorx-story-video-series","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/","title":{"rendered":"RenovoRx Launches \u201cThe RenovoRx Story\u201d Video Series"},"content":{"rendered":"
\n

\nSeries Spotlights the RenovoRx Journey, its Leadership and Innovative <\/i>Treatment Platform Targeting Difficult-to-Treat Cancers<\/i>\n<\/p>\n

LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (\u201cRenovoRx\u201d or the \u201cCompany\u201d) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced the launch of a new video series \u2013 The RenovoRx Story. This video series provides viewers with a unique opportunity to learn more about the Company, its leadership team, and the innovative RenovoTAMP\u2122 (RenovoRx Trans-Arterial Micro-Perfusion) therapeutic platform. Also, highlighted in the video series is the Company\u2019s multi-center TIGeR-PaC Phase 3 clinical trial in locally advanced pancreatic cancer.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are pleased to share this video series telling our story and how our therapy platform is challenging the current paradigm of cancer treatment. For many patients, treatment options are limited to systemic (intravenous) chemotherapy delivered in high concentrations to the entire body. Systemic chemotherapy is often ineffective and associated with debilitating side effects,\u201d said Shaun Bagai, RenovoRx Chief Executive Officer. \u201cThis video series explains the mechanism of action underlying our therapeutic platform, how it differs from systemic chemotherapy, and its potential to extend survival while improving quality of life for cancer patients.\u201d\n<\/p>\n

\nViewers will be introduced to the Company\u2019s CEO, Shaun Bagai, in the first video in the series. The video can be viewed here: https:\/\/renovorx.com\/investors\/news-events\/presentations\/<\/a>. Additional segments to be released in the coming weeks.\n<\/p>\n

\nFor additional information please contact KCSA Strategic Communications by emailing RenovoRx@kcsa.com<\/a>.\n<\/p>\n

\nAbout the Phase 3 TIGeR-PaC Clinical Trial<\/b>\n<\/p>\n

\nTIGeR-PaC is a randomized multi-center Phase 3 study using RenovoRx\u2019s innovative therapy platform, RenovoTAMP\u2122 (RenovoRx Trans-Arterial Micro-Perfusion). The study is evaluating the Company\u2019s first product candidate, RenovoGem, to treat locally advanced pancreatic cancer (LAPC) through the intra-arterial delivery of gemcitabine (an FDA-approved chemotherapy). The study has a primary endpoint of overall survival and several secondary endpoints, including quality of life.\n<\/p>\n

\nTIGeR-PaC is currently enrolling unresectable LAPC patients at several sites across the US. To learn more about the study and the participating clinical trial sites, visit https:\/\/renovorx.com\/clinical-trial\/<\/a><\/b>.\n<\/p>\n

\nAbout RenovoRx, Inc.<\/b>\n<\/p>\n

\nRenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP\u2122) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx\u2019s lead product candidate, RenovoGem\u2122, is a combination of gemcitabine and our patented delivery system, RenovoCath\u00ae<\/sup>, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.\n<\/p>\n

\nRenovoRx\u2019s patent portfolio for its therapy platform and product candidates includes seven U.S. patents, one European patent and several additional patents pending in the US, EU and Asia. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.\n<\/p>\n

\nRenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards \u2013 Life Sciences Edition 2020 for its RenovoTAMP technology.\n<\/p>\n

\nLearn more by visiting the RenovoRx website<\/a> or following us on Facebook<\/a>, LinkedIn<\/a> and Twitter<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the potential of RenovoTAMP\u2122, our ongoing TIGeR-PaC Phase 3 clinical trial in LAPC, and statements regarding the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, clinical trials, therapy platform, business plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these forward-looking statements. These statements may be identified using words such as \u201cmay,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cforecasts,\u201d \u201cestimates,\u201d \u201cintends,\u201d and \u201cpotential,\u201d or the negative of these terms or other comparable terminology regarding RenovoRx\u2019s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our research programs; our ability to use and expand our therapy platform to build a pipeline of product candidates; our ability to advance product candidates into, and successfully complete, clinical trials; the timing or likelihood of regulatory filings and approvals; our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; the commercialization potential of our product candidates, if approved; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; future strategic arrangements and\/or collaborations and the potential benefits of such arrangements; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified personnel; the implementation of our strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the pricing, coverage and reimbursement of our product candidates, if approved; developments relating to our competitors and our industry, including competing product candidates and therapies; negative impacts of the COVID-19 pandemic on our operations; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled \u201cRisk Factors\u201d in documents that we file from time to time with the Securities and Exchange Commission.\n<\/p>\n

\nForward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCompany Contact:<\/b>
RenovoRx, Inc.
\n
Shaun R. Bagai, CEO
\n
Christopher J. Lehman, CFO\n<\/p>\n

\nInvestor Contact:<\/b>
KCSA Strategic Communications
\n
Valter Pinto or Jack Perkins
\n
T: 212-896-1254
\n
RenovoRx@kcsa.com<\/a>\n<\/p>\n

\nMedia Contact:<\/b>
Knight Marketing Communications, Ltd.
\n
Kevin Knight
\n
T: 206-451-4823
\n
kknightpr@gmail.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Series Spotlights the RenovoRx Journey, its Leadership and Innovative Treatment Platform Targeting Difficult-to-Treat Cancers LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (\u201cRenovoRx\u201d or the \u201cCompany\u201d) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced the launch of a new video series \u2013 The RenovoRx Story. This video series provides viewers with a unique … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46120","6":"format-standard","7":"category-industry"},"yoast_head":"\nRenovoRx Launches \u201cThe RenovoRx Story\u201d Video Series - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RenovoRx Launches \u201cThe RenovoRx Story\u201d Video Series - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Series Spotlights the RenovoRx Journey, its Leadership and Innovative Treatment Platform Targeting Difficult-to-Treat Cancers LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (\u201cRenovoRx\u201d or the \u201cCompany\u201d) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced the launch of a new video series \u2013 The RenovoRx Story. This video series provides viewers with a unique ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-13T12:01:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220712005362\/en\/1249215\/21\/RenovoRx_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-launches-the-renovorx-story-video-series\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-launches-the-renovorx-story-video-series\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"RenovoRx Launches \u201cThe RenovoRx Story\u201d Video Series\",\"datePublished\":\"2022-07-13T12:01:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-launches-the-renovorx-story-video-series\\\/\"},\"wordCount\":1188,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-launches-the-renovorx-story-video-series\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005362\\\/en\\\/1249215\\\/21\\\/RenovoRx_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-launches-the-renovorx-story-video-series\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-launches-the-renovorx-story-video-series\\\/\",\"name\":\"RenovoRx Launches \u201cThe RenovoRx Story\u201d Video Series - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-launches-the-renovorx-story-video-series\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-launches-the-renovorx-story-video-series\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005362\\\/en\\\/1249215\\\/21\\\/RenovoRx_logo.jpg\",\"datePublished\":\"2022-07-13T12:01:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-launches-the-renovorx-story-video-series\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-launches-the-renovorx-story-video-series\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-launches-the-renovorx-story-video-series\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005362\\\/en\\\/1249215\\\/21\\\/RenovoRx_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005362\\\/en\\\/1249215\\\/21\\\/RenovoRx_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-launches-the-renovorx-story-video-series\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RenovoRx Launches \u201cThe RenovoRx Story\u201d Video Series\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RenovoRx Launches \u201cThe RenovoRx Story\u201d Video Series - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/","og_locale":"en_US","og_type":"article","og_title":"RenovoRx Launches \u201cThe RenovoRx Story\u201d Video Series - Pharma Trend","og_description":"Series Spotlights the RenovoRx Journey, its Leadership and Innovative Treatment Platform Targeting Difficult-to-Treat Cancers LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (\u201cRenovoRx\u201d or the \u201cCompany\u201d) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced the launch of a new video series \u2013 The RenovoRx Story. This video series provides viewers with a unique ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-13T12:01:51+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220712005362\/en\/1249215\/21\/RenovoRx_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"RenovoRx Launches \u201cThe RenovoRx Story\u201d Video Series","datePublished":"2022-07-13T12:01:51+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/"},"wordCount":1188,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220712005362\/en\/1249215\/21\/RenovoRx_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/","url":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/","name":"RenovoRx Launches \u201cThe RenovoRx Story\u201d Video Series - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220712005362\/en\/1249215\/21\/RenovoRx_logo.jpg","datePublished":"2022-07-13T12:01:51+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220712005362\/en\/1249215\/21\/RenovoRx_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220712005362\/en\/1249215\/21\/RenovoRx_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/renovorx-launches-the-renovorx-story-video-series\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"RenovoRx Launches \u201cThe RenovoRx Story\u201d Video Series"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46120"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46120\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}